

ABT-751

Catalog No: tcsc0495



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

141430-65-1

Formula:

$C_{18}H_{17}N_3O_4S$

Pathway:

Cell Cycle/DNA Damage;Cytoskeleton;Autophagy

Target:

Microtubule/Tubulin;Microtubule/Tubulin;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 48 mg/mL (129.24 mM)

Alternative Names:

E7010

Observed Molecular Weight:

371.41

Product Description


ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC₅₀ of about 1.5 and 3.4 μ M in neuroblastoma and non-neuroblastoma cell lines, respectively.

IC₅₀ Value: 1.5 μ M(neuroblastoma); 3.4 μ M(non-neuroblastoma)

Target: Microtubule/Tubulin

in vitro: ABT-751 shows the selective cytotoxicity with IC₅₀ of 0.6–2.6 μ M in neuroblastoma and 0.7–4.6 μ M in other solid tumor cell lines. Furthermore, ABT-751 also exhibits a selective effect on dynamic microtubules and spares stable microtubules, accounting for the persistence of acetylated and detyrosinated α -tubulin positive polymerized tubules at the IC₉₀ concentration of ABT-751.

in vivo: In Calu-6 xenograft model, ABT-751 as a single agent at 100 and 75 mg/kg/day shows significant antitumor activity, while in combination with cisplatin, ABT-751 shows a dose-dependent enhancement in growth delay. In the HT-29 colon xenograft model, ABT-751 also shows significant antitumor activity as a single agent and produced a dose-dependent enhancement in growth delay. In combination with 5-FU. In dogs with lymphoma, ABT-751 exhibits the dose-limiting toxicities that included vomiting, diarrhea, anorexia, or some combination of these with a maximum tolerated dose (MTD) of 350 mg/m² PO q24h. Furthermore, the mean AUC and C_{max} for ABT-751 at the MTD of 350 mg/m² is 5.55 μ g-hour/mL and 0.9 μ g/mL, respectively.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!